Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 06, 2015 8:41 AM ET


Company Overview of Cephalon, Inc.

Company Overview

Cephalon, Inc. engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. It offers NUVIGIL (armodafinil) tablets for improving wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea and shift work disorder, also known as shift work disorder and narcolepsy; TREANDA (bendamustine HCl) for injection for the treatment of patients with chronic lymphocytic leukemia; and AMRIX (Cyclobenzaprine Hydrochloride extended-release capsules), which is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute and painful musculoskeletal conditions. The company also provi...

41 Moores Road

Frazer, PA 19355

United States

Founded in 1987

3,726 Employees





Key Executives for Cephalon, Inc.

Chief Executive Officer and Director
Age: 60
Chief Financial Officer, Principal Accounting Officer and Executive Vice President
Age: 57
Executive Vice President and President of Cephalon Europe Operations
Age: 63
Executive Vice President, Secretary and General Counsel
Age: 51
Chief Medical Officer and Executive Vice President
Age: 54
Compensation as of Fiscal Year 2015.

Cephalon, Inc. Key Developments

Faruqi & Faruqi, LLP and Berger & Montague,P.C. Reach Whistleblower Lawsuit Settlement with AstraZeneca Pharmaceuticals LP, Cephalon, Inc., and Biogen Inc

Faruqi & Faruqi, LLP and co-counsel Berger & Montague,P.C. announced that they have reached a settlement in three separate but related whistleblower lawsuits alleging violations of the False Claims Act against AstraZeneca Pharmaceuticals LP, Cephalon, Inc., and Biogen Inc., for a total of $55.5 million. The cases were jointly prosecuted by Faruqi & Faruqi, LLP and Berger & Montague, P.C. on behalf of Relator Ronald J. Streck, who filed this action in 2008. Under the terms of the settlement, AstraZeneca will pay $46.5 million, Cephalon will pay $7.5 million, and Biogen will pay $1.5 million. Claims against a fourth drug manufacturer, Genzyme Corporation, are still being litigated. The case, pending in federal court in the Eastern District of Pennsylvania, is captioned United States ex rel. Ronald Streck versus Allergan, et al., Case No. 08-cv-5135. The lawsuit, filed on behalf of the United States under the False Claims Act (FCA) and State False Claims Acts alleges that a number of pharmaceutical manufacturers, including AstraZeneca, Cephalon and Biogen, fraudulently underpaid mandatory rebates to state Medicaid programs. Streck's lead attorney, T. Talyana Bromberg of Faruqi & Faruqi, LLP, stated: "When pharmaceutical companies manipulate prices in order to underpay Medicaid, every taxpayer suffers.

FTC Reaches Settlement with Cephalon Resolving the Commission's Antitrust Suit

The Federal Trade Commission has reached a settlement resolving the Commission's antitrust suit charging Cephalon, Inc. with illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil. The settlement ensures that Teva Pharmaceutical Industries Ltd., which acquired Cephalon in 2012, will make a total of $1.2 billion available to compensate purchasers, including drug wholesalers, pharmacies, and insurers, who overpaid because of Cephalon's illegal conduct. Some of these purchasers have settled related litigation and payments made by Teva in those or other actions can be credited against the FTC fund according to the terms of the stipulated order for equitable monetary relief. Any remaining funds will be paid to the U.S. Treasury. As part of the settlement, Teva also has agreed to a prohibition on the type of anticompetitive patent settlements that Cephalon used to artificially inflate the price of Provigil.

Actavis plc Inks Deal with Cephalon Settling Nuvigil Patent Challenge

Actavis entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvig (armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg). Nuvigil is a prescription medicine indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD) or narcolepsy. Under the terms of the agreement, Cephalon will grant Actavis a license to market generic versions of 100 mg and 200 mg Nuvigil beginning on June 1, 2016, or earlier under certain circumstances. Cephalon will also grant Actavis a license to market generic versions of 50 mg, 150 mg and 250 mg Nuvigilà ® beginning 180 days after the initial launch of generic versions of those dosage strengths. Other details of the settlement were not disclosed.

Similar Private Companies By Industry

Company Name Region
Boehringer Ingelheim Pharmaceuticals, Inc. United States
Genemed Biotechnologies, Inc. United States
Rempex Pharmaceuticals, Inc. United States
Metrium Partners 1, Inc. United States
Maharishi Ayurveda Products International, Inc. United States

Recent Private Companies Transactions

March 17, 2015
Cephalon, Inc., Worldwide Rights and Assets to Four Oncology Development Programs

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cephalon, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at